James F. Barter, MD

Gynecologic Oncology, Gynecology, Gynecological Surgery

Undergraduate: Washington and Lee University
Medical School: University of Virginia School of Medicine (1977)
Internship: University of Kentucky Hospital (1979)
Residency: Duke University (1983)
Fellowship: University of Birmingham, Gynecologic Oncology (1986)
Board Certifications: Gynecologic Oncology, Gynecology
Languages: English


To make an appointment:

Call (301) 770-4967

Patient Testimonials

About Dr. Barter:

Dr. Barter is Director of Gynecologic Oncology Research at Holy Cross Hospital, Silver Spring, Maryland.  He has an active Gynecologic Oncology practice performing 700 surgical cases per year, and has done approximately 1400 da Vinci systems robotic surgeries.  He has lectured nationally and internationally on robotic surgery.  As director of research, he has personally put on 1300 patients on various surgical and cancer related protocols in the last 10 years.  Current protocols include utilization of PARP inhibitors in ovarian cancer, PDL-1 in various gynecologic cancers, and the Pneumoliner device.  He has published about 50 scientific articles and was quoted in Wall Street Journal regarding uterine morcellation.

Dr. Barter has been very involved in research - below are the list of trials that he has participated in:

Research Study Title

1. Serum Proteomics: For Detection of Ovarian Cancer Using the Correlogic Systems, Inc. Serum Pattern blood Test.


2. GOG–0218: A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab in Patients With Ovarian Cancer


3. ChemoFx ®  PRO,  a post –market data collection study utilizing physician report outcomes


4. Bristol-Myers Squibb: A Phase III Open Label, Randomized Study of Ixabepilone Versus Paclitaxel Or Doxorubicin in Women with Advanced Endometrial Cancer.


5. GOG-0252: Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Ovarian Epithelial Cancer


6. Effectiveness of Radio-Frequency Surgical Detection System


7. Millennium Pharmaceuticals, Inc.: Randomized Phase 2 Study of an Aurora A Kinase Inhibitor, Plus Weekly Paclitaxel or Weekly Paclitaxel Alone in Patients with Recurrent Ovarian Cancer


8. GOG–0262: Phase III Trial of Every-3-weeks Paclitaxel vs. Dose Dense Weekly Paclitaxel in Combination with Caboplatin Plus Concurrent and Consolidation Bevacizumab in the Treatment of Epithelial Ovarian Cancer


9. A Randomized Phase II Evaluation of Carboplatin/Paclitaxel with and without Trastuzumab (Herceptin®) in Her2/neu+ Patients with Advanced/Recurrent Uterine Serous Papillary Carcinoma, Sponsor: Yale University School of Medicine


10. GOG 258: Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer


11. EMR 200066_012( Serono) Phase II Randomized Double Blind Placebo Controlled Trial of Combination of Pimasertib with SAR245409 or of Pimasertib with SAR245409 Placebo in Subjects with Previously Treated Unresectable Low Grade Ovarian Cancer


12. A Phase 1/2a, open-label, parallel, two-arm dose-escalation study to assess the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of BAX69 in subjects with refractory ovarian cancer with malignant ascites.


13. Forward1: a randomized, open label phase 3 study to evaluate the safety and efficacy of mirvetuximab soravtansine (imgn853) versus investigator’s choice of chemotherapy in women with folate receptor alpha positive advanced epithelial ovarian cancer, primary peritoneal cancer or primary fallopian tube cancer.


14. PRIMA : A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy


15. Phase II single arm trial with combination of Everolimus and Letrozole in treatment of platinum resistant relapse or refractory or persistent ovarian cancer/endometrial cancer


16. Non-Randomized, Open-Label Phase II Study to Assess Olaparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That Have Received at Least 2 Prior Lines of Chemotherapy


17. A Randomized, Open-Label, Multicenter, Phase 3  Study to Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with and/or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)


18. Uterine surgery utilizing the FDA approved Pneumo-liner contained morcellation system


19. An open-label, randomized, phase 3 clinical trial of regn2810 versus therapy of investigator's choice chemotherapy in recurrent or metastatic platinumrefractory cervical carcinoma


20. A phase III, multicenter, randomized, study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly diagnosed stage iii or stage iv ovarian, fallopian tube, or primary peritoneal cancer


21. Tesaro – First : A randomized, double-blind, phase 3 comparison of platinum-based therapy with tsr-042 and niraparib versus standard of care platinum-based therapy as first-line treatment of stage III or IV nonmucinous epithelial ovarian cancer


Correlogic Systems, Inc



NCI/NIH Government sponsored



Precision Therapeutics, Incorporated


Bristol-Myers Squibb



NCI/NIH Government sponsored


RF Surgical Systems, Inc.


Millennium Pharmaceuticals, Inc



NCI/NIH Government sponsored



Yale University School of Medicine




NCI/NIH Government sponsored



EMD Serono Inc., One Technology Place, Rockland, MA 02370, USA



Baxalta US Inc.




ImmunoGen, Inc.





















PI Initiated





F. Hoffmann-La Roche Ltd







Activation at Holy Cross Hospital

April 2005



January 2008



October 2008



September 2009



November 2009


April 2010


4Qtr 2010



November 2010




December 2012





April 2013



October 2013



October 2015




May 2016





July  2016




July  2016



December 2016





April 2017





September 2017


October 2017



July 2018




July 2018






6301 Executive Blvd
Rockville, MD 20852

Parking: FREE




12800 Middlebrook Rd, Suite 480
Germantown, MD 20874

Parking: FREE